SCI — Investor Presentation 2014

Jul 31, 2014

SCI PHARMTECH, ING.

簡報

procedure Thainform Forwardterium Leola

All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon

Xol ardAckion, Enabled a False and r

CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way

d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add

DES

RicertyTodes is Newtodes: ar brownsteads then hegin

Doctor Course I'm Falue.

Mel Andex ; a UEZ; Ituna, Index02

AE MANDICON - - 1 About

UP J. ftems, Promer (0, U914

員工數Employee:197 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣662佰萬元(NTD 662mn) 營業項目Business: 原料藥API(30.60%) 中間體Intermediate(57.63%) 特用化學品 Custom-made chemicals(11.77%)

公司概況Outline

	Y2013	Y2014 to date
歐 洲Europe	36.01%	44.54%
美 洲America	22.80%	23.11%
亞 洲Asia	24.00%	17.23%
國 內Taiwan	17.19%	14.03%
洲Australia 澳	0.00%	1.09%
計Total 合	100.00%	100.00%

Unit: K NTD

	2013	2014 to date
營收Sales	1,292,734	791,015
營業成本COGS	(895,753)	(532,717)
毛利Gross Profit	396,981	258,298
毛利率 GP Ratio	30.7%	32.7%
營業費用Operating Expenses	(191,122)	(96,158)
營業利益Operating Income	205,859	162,140
營業外損益Non-Operating In/Ex	(12,079)	35,947
稅前淨利 Net Profit before Tax	193,780	198,087
所得稅Income Tax	(33,842)
本期淨利Net Profit after Tax	159,938

產品組合-Products

Y2011	$\frac{0}{0}$
Di-VaNa	24.51%
PGA	17.65%
V.A.	13.76%
PPON	10.70%
M85	5.25%
Pent-2	3.73%
DBS	3.08%
M115	2.55%
M74	2.31%
NBE	$1.87\%$
Total	85.40%

Y2011	%	Y2012	%	Y2013	%
Di-VaNa	24.51%	V.A.	18.66%	PGA	18.31%
PGA	17.65%	PGA	16.61%	Di-VaNa	16.92%
V.A.	13.76%	Di-VaNa	15.97%	S20/38	8.39%
PPON	10.70%	PPON	7.88%	V.A.	8.23%
M85	5.25%	Pent-2	4.78%	LPF.Na	6.58%
Pent-2	3.73%	5-HMT	4.33%	PPON	6.53%
DBS	3.08%	M85	3.89%	5-HMT	4.51%
M115	2.55%	DBS	2.73%	PEB.Na	3.98%
M74	2.31%	M115	2.59%	NaVa	3.34%
NBE	1.87%	M74	2.18%	DBS	2.63%
Total	85.40%	Total	79.62%	Total	79.42%

No.	Product	$\frac{0}{0}$	Sales (NT\$)
1	PGA	16.39%	129,627,876
$\overline{2}$	S20/38	12.35%	97,658,745
3	V.A.	7.29%	57,633,546
$\overline{\mathbf{4}}$	LPF.Na	6.41%	50,709,144
5	Di-VANa	6.14%	48,585,968
6	Pent-2	4.61%	36,447,424
$\overline{\mathbf{7}}$	DBS	4.54%	35,902,486
8	NaVA	4.45%	35,216,755
9	5-HMT	3.89%	30,743,040
10	PPON	3.56%	28,175,384

SCI

Di-Va (Depakote) ER/DR

NaVa

V DEDPM.

$\rightarrow VA$

學名藥於2009推出 Generic came out in 2009

產品介紹Product

Valproic Acid (VA)

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customers

Pentobarbital Sodium

Anti-inflammatory (Loxoprofen sodium) 2012年銷售5佰萬 5 mn sales in 2012. 2013年銷售85佰萬 85 mn sales in 2013 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg

S20/38

5-HMT – Ritonavir,Lopinavir

• Antidepressant ( Duloxetine )

2013年底專利到期 Patent expired in the end of 2013

• 10個客戶 10 customers
• 中間體為S-MMAA(Intermediate)

近三年營業額約1仟萬 close to 10 mn sales over 3 years

Lorcaserin

Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API

GMP Status(GMP現況)

API	CGMP certified	CEP (EDQM)	DMF (USA)	MF (Japan)	DMF (Canada)
	(TFDA)
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011
Probucol	2004		2004
Sodium Valproate	2004	2006
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006
Pentobarbital Sodium	2009	2 011
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2 011	2014
Duloxetine Hydrochloride	2012	2014	2010/2011
Thiopental acid	2012
Loxoprofen Sodium Hydrate	2012			2011
Articaine Hydrochloride	2013	2014
Hydroxychloroquine Sulfate	2014		2014
Clindamycin Palmitate HCl			2011
Cyclophosphamide			2012

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

敬 請 指 教